GSK在2025年取得了强有力的成果,利润和收入在特殊药品和一项重大解决方案的推动下不断增长,同时计划削减研发工作并侧重于肥胖症治疗。 GSK posted strong 2025 results, with rising profits and revenue, driven by specialty medicines and a major settlement, while planning R&D job cuts and focusing on obesity treatments.

GlaxoSmithKline(GlaxoSmithKline)报告2025年成果强劲,收入增长4%,达到327亿英镑,核心业务利润增长7%,其驱动力是呼吸道、免疫学和艾滋病毒治疗方面对特殊药品的强劲需求。 GlaxoSmithKline reported strong 2025 results with a 4% revenue increase to £32.7 billion and a 7% rise in core operating profits, driven by robust demand for specialty medicines in respiratory, immunology, and HIV treatments. 该公司的净利润翻了一番多,达到57亿英镑,这得益于与Zantac相关的诉讼和23亿美元和解的恢复。 The company’s net profit more than doubled to £5.7 billion, aided by the recovery from Zantac-related lawsuits and a $2.3 billion settlement. 首席执行官Luke Miels于1月接任,强调研发方面的进展,包括五个主要产品批准,并宣布购置22亿美元的RAPT治疗药物。 CEO Luke Miels, who took over in January, highlighted progress in R&D, including five major product approvals, and announced a $2.2 billion acquisition of RAPT Therapeutics. GGSK提高了股息,重申长期目标,并预测2026年的中等利润增长7%至9%,同时计划在美国和英国削减350个研发工作职位。 GSK raised its dividend, reaffirmed long-term targets, and forecast moderate 2026 profit growth of 7% to 9%, while planning up to 350 R&D job cuts in the US and UK. 该公司重申其侧重于与肥胖有关的治疗,而不是减重药物,并预期疫苗和一般药品销售会放缓。 The company reiterated its focus on obesity-related treatments over weight-loss drugs and expects a slowdown in vaccine and general medicines sales.